Related Experiment Video
Updated: Jul 7, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
mTOR pathway in renal cell carcinoma.
Sara C Hanna1, Samuel A Heathcote, William Y Kim
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Chapel Hill, NC 27599, USA. sara_hanna@med.unc.edu
Expert Review of Anticancer Therapy
|February 19, 2008
Summary
Targeting the mTOR pathway shows promise for advanced renal cell carcinoma, particularly for nonclear cell types. This approach offers new hope where previous treatments were limited.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) historically had limited treatment options.
- Early targeted therapies focused on hypoxia-inducible factor (HIF) pathway inhibitors, like VEGF.
- Recent advancements include mTOR inhibitors, showing efficacy in patients with poor prognostic features.
Purpose of the Study:
- To review the mechanistic role of the mTOR pathway in clear cell and nonclear cell renal cell carcinoma.
- To discuss the clinical benefit of mTOR inhibitors in advanced RCC.
- To contextualize mTOR inhibition within the evolving landscape of RCC therapeutics.
Main Methods:
- Literature review of preclinical and clinical studies on mTOR pathway inhibitors in renal cell carcinoma.
- Analysis of data regarding efficacy in different RCC histologies and prognostic groups.
- Synthesis of information on the molecular mechanisms linking mTOR, HIF, and RCC.
Main Results:
- mTOR inhibition demonstrates clinical benefit in advanced RCC, especially in patients with poor prognostic features.
- Preclinical data suggest mTOR inhibition leads to HIF downregulation.
- Notably, patients with nonclear cell RCC histology appear to benefit from mTOR inhibitors.
Conclusions:
- The mTOR pathway is a relevant therapeutic target in both clear cell and nonclear cell RCC.
- mTOR inhibitors represent a significant advancement in the treatment of advanced renal cell carcinoma.
- This pathway's inhibition offers a promising strategy amidst rapidly expanding treatment options for RCC.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:54Canonical Wnt Signaling Pathway
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
01:41Non-Canonical Wnt Signaling Pathways
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...